Noni Maui, a Division of Noni Biotech International Becomes Official Supplier of University of Hawaii Cancer Research Center NIH

Noni Maui, a Division of Noni Biotech International Becomes Official Supplier of University of Hawaii Cancer Research Center NIH
A new International Hawaiian Noni Biotech Company has recently announced that it is the official supplier of dehydrated Noni capsules to the University of Hawaii’s Cancer Research Center’s human trials. A study funded by the NIH and under the direction of Dr. Brian Issell MD, Oncologist and Director of the U of H Cancer Research Center, will attempt to establish the efficacy of using Noni capsules for treating cancer patients. Phase I will attempt to establish the proper Hawaiian Noni capsule dosage that will affect the patients quality of life, reduce pain levels and assist with defense of cancer growth. (PRWeb Oct 31, 2006) Trackback URI: http://www.prweb.com/dingpr.php/Q291cC1IYWxmLVByb2YtU2luZy1NYWduLVplcm8=

Biotech Gathering Has Trans-Pacific Perspective (San Diego Business Journal)

Biotech Gathering Has Trans-Pacific Perspective (San Diego Business Journal)
The Sino-American Biotechnology and Pharmaceutical Professionals Association is hosting its second annual Pacific Forum on Nov. 4. The conference is set for 8:30 a.m.-4 p.m. at the Institute of the Americas at UC San Diego.

Rice farmers fear, loathe biotech grains (Contra Costa Times)

Rice farmers fear, loathe biotech grains (Contra Costa Times)
Fourth-generation farmer Greg Massa was in the middle of the rice harvest and he was dirty, angry and depressed. The price of the gasoline that powers his water pumps and rice harvester had never been more expensive. A late planting season, hot summer and rising expenses had ensured a less-than-stellar harvest, with the U.S. Department of Agriculture forecasting a 13 percent drop compared with

Millions spent on biotech will pay off, scientists say (Sun-Sentinel)

Millions spent on biotech will pay off, scientists say (Sun-Sentinel)
Port St. Lucie · Biotechnology will cost the Treasure Coast and the rest of Florida hundreds of millions of dollars.

Biotech QLT to cut 80 jobs after Q3 loss - Vancouver Sun (subscription)

Biotech QLT to cut 80 jobs after Q3 loss - Vancouver Sun (subscription)
Biotech QLT to cut 80 jobs after Q3 lossVancouver Sun (subscription), Canada - 34 minutes ago… conference call. “During this process we even considered whether we should revert to being an early-stage biotech company. “However …

Eli Lilly expands biotech complex in Indianapolis (PharmaBiz)

Eli Lilly expands biotech complex in Indianapolis (PharmaBiz)
Eli Lilly and Company has announced completion of the first phase of a $560 million expansion to its biotech complex in Indianapolis. The investment is part of a $1 billion effort to strengthen and build the company’s biotechnology drug research and development capabilities.

Lilly injects $560m into US biotech plant expansion but will shut … - In-PharmaTechnologist.com

Lilly injects $560m into US biotech plant expansion but will shut … - In-PharmaTechnologist.com
INDYchannel.comLilly injects $560m into US biotech plant expansion but will shut …In-PharmaTechnologist.com, France - 40 minutes ago25/10/2006 - Drug maker Eli Lilly has completed the first phase of a $560m (?446m) expansion of its biotech facility in Indianapolis, US, in order to match … Lilly Biotech Complex Two-Thirds Done MSN MoneyEli Lilly completes first phase of biotech expansion MarketWatchLilly opens $560M Biotech plant WTHRINDYchannel.com - Trading Marketsall 14 news articles

Biotech draws lion’s share of shrinking venture dollars

Biotech draws lion’s share of shrinking venture dollars
Biotechnology edged out computer software as the industry sector attracting the most venture capital in the third quarter, as overall venture investments dropped by 8 percent from the previous quarter, according to the MoneyTree survey released yesterday.

ANALYST OUTLOOK: Polish biotech firm Bioton earns maintained “hold”rating from CA-IB (Interfax)

ANALYST OUTLOOK: Polish biotech firm Bioton earns maintained “hold”rating from CA-IB (Interfax)
WARSAW. OCTOBER 23. INTERFAX CENTRAL EUROPE - Human insulin maker Bioton earned a maintained “hold” recommendation with an estimated fair value of PLN 2.50 per paper from CA-IB, the brokerage house wrote in a report dated October 16.

Eli Lilly ready for renewed focus on biotech (The Indianapolis Star)

Eli Lilly ready for renewed focus on biotech (The Indianapolis Star)
A hulking, 800,000-square-foot bricked complex on Kentucky Avenue stands as a key to the future of Eli Lilly and Co.

Next Page »